Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Locoregional failure remains the principal mode of mortality in head and neck squamous cell
carcinoma (HNSCC) treated with conventional chemoradiation therapy. Magnetic resonance-guided
radiation therapy (MRgRT) allows for adaptive radiation dose escalation based on tumor
response and may improve therapeutic outcomes while limiting toxicities.
This protocol evaluates a novel framework for radiation delivery with concurrent atezolizumab
in patients with advanced HNSCC. Dose-Escalated Hypofractionated Adaptive Radiotherapy
(DEHART) modifies radiation dose using MRgRT by escalating radiation dose to residual tumor
while deescalating radiation dose to areas of tumor regression.